Indian Adviser Urges More Attention to Gender-Specific Drugs
This article was originally published in PharmAsia News
An adviser at India's National Institute of Immunology says the country should place more emphasis on the differences between drugs for males and those for females. N.K. Ganguly said the country currently produces drugs focused on the needs of men while ignoring the needs of women even though the needs of each are quite different. India has developed about 30 life-saving drugs in the past few years, Ganguly said, but many are neither compatible nor affordable for Indian women. He urged drug makers to consider the changing needs of the country. (Click here for more
You may also be interested in...
Purdue pleads guilty to three felony charges over marketing of OxyContin under settlement that requires Purdue to be dissolved and transformed into an entity that provides addiction and overdose medicines. Twenty-five state AGs oppose creation of a PBC, arguing Purdue should be sold to another company.
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.